A Combination of Pathway-Targeted Inhibitor with DNA-Repair Inhibitor: Preclinical Efficacy of Zactima and Olaparib in Triple Negative Subset of Breast Cancer.

被引：0
|
作者：
Dey, N. [1 ]
Wu, H. [1 ]
Sun, Y. [1 ]
De, P. [1 ]
Leyland-Jones, B. [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P3-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-18-02
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evaluation of a novel PELP1 inhibitor for treatment of triple negative breast cancer.
    Altwegg, Kristin A.
    Viswanadhapalli, Suryavathi
    Liu, Junhao
    Liu, Zexuan
    Pratap, Uday P.
    Vankayalapati, Hariprasad
    Vadlamudi, Ratna K.
    CANCER RESEARCH, 2021, 81 (13)
  • [22] Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer
    Cyprian, Farhan S.
    Akhtar, Saghir
    Gatalica, Zoran
    Vranic, Semir
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2019, 19 (03) : 227 - 233
  • [23] Safety and efficacy of eribulin in combination with gemcitabine in patients with advanced triple negative breast cancer.
    Michalaki, Vasiliki
    Fragulidis, Georgios
    Kondis, Ioannis
    Karvouni, Eleni
    Dafnios, Nikolaos
    Kotsiou, Antonia
    Vassiliou, Ioannis
    Papadimitriou, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Preclinical study of Dbait, an inhibitor of three DNA repair pathways, in breast cancer treatment
    Dutreix, Marie
    Kirova, Youlia M.
    Croset, Amelia
    Devun, Flavien
    Sun, Jian-Sheng
    CANCER RESEARCH, 2013, 73 (08)
  • [25] Preclinical efficacy of a dual PI3K-mTOR inhibitor, BEZ235 in triple negative breast cancer
    Dey, N.
    Wu, H.
    Sun, Y.
    De, P.
    Leyland-Jones, B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S17 - S17
  • [26] Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer
    Wu, Kunlin
    Zhang, Huihao
    Zhou, Linlin
    Chen, Ling
    Mo, Caiqin
    Xu, Sunwang
    Lin, Junyu
    Kong, Lingjun
    Chen, Xiangjin
    EXPERIMENTAL CELL RESEARCH, 2022, 421 (01)
  • [27] The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo
    Pang, Yuheng
    Shi, Runze
    Chan, Liujia
    Lu, Yu
    Zhu, Di
    Liu, Tong
    Yan, Meisi
    Wang, Yuji
    Wang, Wenjing
    PHARMACOLOGICAL RESEARCH, 2023, 196
  • [28] Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
    Westin, S.
    Litton, J.
    Williams, R.
    Soliman, P.
    Frumovitz, M.
    Schmeler, K.
    Jazaeri, A.
    Sood, A.
    Lu, K.
    Moulder, S.
    Murthy, R.
    Rodriguez, A.
    Samuel, C.
    Engerman, L.
    Cyriac, A.
    Rugman, P.
    Lindemann, J.
    McMurtry, E.
    Mills, G.
    Coleman, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells
    Rao, Rekha
    Balusu, Ramesh
    Fiskus, Warren
    Mudunuru, Uma
    Venkannagari, Sreedhar
    Chauhan, Lata
    Smith, Jacqueline E.
    Hembruff, Stacey L.
    Ha, Kyungsoo
    Atadja, Peter
    Bhalla, Kapil N.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (04) : 973 - 983
  • [30] Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
    Simiczyjew, Aleksandra
    Dratkiewicz, Ewelina
    Van Troys, Marleen
    Ampe, Christophe
    Styczen, Ilona
    Nowak, Dorota
    CANCERS, 2018, 10 (09)
12345